Mind-boggling! – Aftermath of Tofacitinib FDA Hearing Part 2
After the FDA Arthritis Advisory Committee (AAC) hearing earlier this month for Pfizer’s new oral treatment for RA, tofacitinib, we looked at the four distinct votes of the AAC and some of the ways the media responded to them. They ranged from serious to pitiful to laughable. But there’s more.
3 news bytes that might...Continue reading 14 Comments »
Read more